Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice

Sun Woo Yoon, Tae Young Lee, Sung Jin Kim, Il Han Lee, Moon Hee Sung, Jong Sup Park, Haryoung Poo

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The human papillomavirus (HPV) minor capsid protein, L2, is a good candidate for prophylactic vaccine development because L2-specific antibodies have cross-neutralizing activity against diverse HPV types. Here, we developed a HPV mucosal vaccine candidate using the poly-γ-glutamic acid synthetase A (pgsA) protein to display a partial HPV-16 L2 protein (N-terminal 1-224 amino acid) on the surface of Lactobacillus casei (L. casei). The oral immunization with L. casei-L2 induced productions of L2-specific serum IgG and vaginal IgG and IgA in Balb/c mice. To examine cross-neutralizing activity, we used a sensitive high-throughput neutralization assay based on HPV-16, -18, -45, -58, and bovine papillomavirus 1 (BPV1) pseudovirions. Our results revealed that mice vaccinated with L. casei-L2 not only generated neutralizing antibodies against HPV-16, but they also produced antibodies capable of cross-neutralizing the HPV-18, -45, and -58 pseudovirions. Consistent with previous reports, vaccination with HPV-16 L1 virus-like particles (VLPs) failed to show cross-neutralizing activity. Finally, we found that oral administration of L. casei-L2 induced significant neutralizing activities against genital infection by HPV-16, -18, -45, and -58 pseudovirions encoding a fluorescence reporter gene. These results collectively indicate that oral administration of L2 displayed on L. casei induces systemic and mucosal cross-neutralizing effects in mice.

Original languageEnglish (US)
Pages (from-to)3286-3294
Number of pages9
JournalVaccine
Volume30
Issue number22
DOIs
StatePublished - May 9 2012
Externally publishedYes

Fingerprint

Human papillomavirus 16
Lactobacillus casei
neutralization
oral administration
Oral Administration
Human papillomavirus 18
Papillomaviridae
mice
Bovine papillomavirus 1
Immunoglobulin G
Papillomavirus Vaccines
polyglutamic acid
Antibodies
Capsid Proteins
oral vaccination
Ligases
Neutralizing Antibodies
antibodies
virus-like particles
Reporter Genes

Keywords

  • Cross-neutralization
  • HPV-16 L2
  • Lactobacillus casei
  • Mucosal immunity

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. / Yoon, Sun Woo; Lee, Tae Young; Kim, Sung Jin; Lee, Il Han; Sung, Moon Hee; Park, Jong Sup; Poo, Haryoung.

In: Vaccine, Vol. 30, No. 22, 09.05.2012, p. 3286-3294.

Research output: Contribution to journalArticle

Yoon, Sun Woo ; Lee, Tae Young ; Kim, Sung Jin ; Lee, Il Han ; Sung, Moon Hee ; Park, Jong Sup ; Poo, Haryoung. / Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. In: Vaccine. 2012 ; Vol. 30, No. 22. pp. 3286-3294.
@article{19e0d11a96c24ffa9bff2af7ff414a6e,
title = "Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice",
abstract = "The human papillomavirus (HPV) minor capsid protein, L2, is a good candidate for prophylactic vaccine development because L2-specific antibodies have cross-neutralizing activity against diverse HPV types. Here, we developed a HPV mucosal vaccine candidate using the poly-γ-glutamic acid synthetase A (pgsA) protein to display a partial HPV-16 L2 protein (N-terminal 1-224 amino acid) on the surface of Lactobacillus casei (L. casei). The oral immunization with L. casei-L2 induced productions of L2-specific serum IgG and vaginal IgG and IgA in Balb/c mice. To examine cross-neutralizing activity, we used a sensitive high-throughput neutralization assay based on HPV-16, -18, -45, -58, and bovine papillomavirus 1 (BPV1) pseudovirions. Our results revealed that mice vaccinated with L. casei-L2 not only generated neutralizing antibodies against HPV-16, but they also produced antibodies capable of cross-neutralizing the HPV-18, -45, and -58 pseudovirions. Consistent with previous reports, vaccination with HPV-16 L1 virus-like particles (VLPs) failed to show cross-neutralizing activity. Finally, we found that oral administration of L. casei-L2 induced significant neutralizing activities against genital infection by HPV-16, -18, -45, and -58 pseudovirions encoding a fluorescence reporter gene. These results collectively indicate that oral administration of L2 displayed on L. casei induces systemic and mucosal cross-neutralizing effects in mice.",
keywords = "Cross-neutralization, HPV-16 L2, Lactobacillus casei, Mucosal immunity",
author = "Yoon, {Sun Woo} and Lee, {Tae Young} and Kim, {Sung Jin} and Lee, {Il Han} and Sung, {Moon Hee} and Park, {Jong Sup} and Haryoung Poo",
year = "2012",
month = "5",
day = "9",
doi = "10.1016/j.vaccine.2012.03.009",
language = "English (US)",
volume = "30",
pages = "3286--3294",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "22",

}

TY - JOUR

T1 - Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice

AU - Yoon, Sun Woo

AU - Lee, Tae Young

AU - Kim, Sung Jin

AU - Lee, Il Han

AU - Sung, Moon Hee

AU - Park, Jong Sup

AU - Poo, Haryoung

PY - 2012/5/9

Y1 - 2012/5/9

N2 - The human papillomavirus (HPV) minor capsid protein, L2, is a good candidate for prophylactic vaccine development because L2-specific antibodies have cross-neutralizing activity against diverse HPV types. Here, we developed a HPV mucosal vaccine candidate using the poly-γ-glutamic acid synthetase A (pgsA) protein to display a partial HPV-16 L2 protein (N-terminal 1-224 amino acid) on the surface of Lactobacillus casei (L. casei). The oral immunization with L. casei-L2 induced productions of L2-specific serum IgG and vaginal IgG and IgA in Balb/c mice. To examine cross-neutralizing activity, we used a sensitive high-throughput neutralization assay based on HPV-16, -18, -45, -58, and bovine papillomavirus 1 (BPV1) pseudovirions. Our results revealed that mice vaccinated with L. casei-L2 not only generated neutralizing antibodies against HPV-16, but they also produced antibodies capable of cross-neutralizing the HPV-18, -45, and -58 pseudovirions. Consistent with previous reports, vaccination with HPV-16 L1 virus-like particles (VLPs) failed to show cross-neutralizing activity. Finally, we found that oral administration of L. casei-L2 induced significant neutralizing activities against genital infection by HPV-16, -18, -45, and -58 pseudovirions encoding a fluorescence reporter gene. These results collectively indicate that oral administration of L2 displayed on L. casei induces systemic and mucosal cross-neutralizing effects in mice.

AB - The human papillomavirus (HPV) minor capsid protein, L2, is a good candidate for prophylactic vaccine development because L2-specific antibodies have cross-neutralizing activity against diverse HPV types. Here, we developed a HPV mucosal vaccine candidate using the poly-γ-glutamic acid synthetase A (pgsA) protein to display a partial HPV-16 L2 protein (N-terminal 1-224 amino acid) on the surface of Lactobacillus casei (L. casei). The oral immunization with L. casei-L2 induced productions of L2-specific serum IgG and vaginal IgG and IgA in Balb/c mice. To examine cross-neutralizing activity, we used a sensitive high-throughput neutralization assay based on HPV-16, -18, -45, -58, and bovine papillomavirus 1 (BPV1) pseudovirions. Our results revealed that mice vaccinated with L. casei-L2 not only generated neutralizing antibodies against HPV-16, but they also produced antibodies capable of cross-neutralizing the HPV-18, -45, and -58 pseudovirions. Consistent with previous reports, vaccination with HPV-16 L1 virus-like particles (VLPs) failed to show cross-neutralizing activity. Finally, we found that oral administration of L. casei-L2 induced significant neutralizing activities against genital infection by HPV-16, -18, -45, and -58 pseudovirions encoding a fluorescence reporter gene. These results collectively indicate that oral administration of L2 displayed on L. casei induces systemic and mucosal cross-neutralizing effects in mice.

KW - Cross-neutralization

KW - HPV-16 L2

KW - Lactobacillus casei

KW - Mucosal immunity

UR - http://www.scopus.com/inward/record.url?scp=84862804637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862804637&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.03.009

DO - 10.1016/j.vaccine.2012.03.009

M3 - Article

C2 - 22426329

AN - SCOPUS:84862804637

VL - 30

SP - 3286

EP - 3294

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 22

ER -